Feature | December 23, 2013

PCI Performance Measures Include Patient Selection, Appropriateness

Measures examine care before, during, after procedure

December 23, 2013 — Careful documentation of patient selection and procedure appropriateness are critical — yet underutilized — steps in ensuring high-quality clinical care for percutaneous coronary intervention (PCI), according to performance measures released by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society for Cardiovascular Angiography and Interventions (SCAI), the AMA-Convened Physician Consortium for Performance Improvement and the National Committee for Quality Assurance (NCQA).
 
Designed to benchmark and improve the quality of PCI, the set of performance measures includes 11 measures that address both ambulatory and inpatient settings, with two measures that address documentation and appropriateness. The document focuses primarily on elective PCI.
 
The new set of measures breaks important ground for performance measurement examining care before, during and after the procedure. It is the first set of cardiovascular performance measures to directly address procedure appropriateness. In addition, the measures incorporate other indicators of quality such as procedural volume and whether the institution benchmarks care by participating in regional or national registries.
 
The 11 measures are:
  1. Comprehensive documentation of the reasons for PCI
  2. An appropriate reason for elective PCI  (benefits outweigh the risks)  
  3. An evaluation of the individual’s ability to receive dual antiplatelet therapy (conducted before the procedure)
  4. The use of embolic protection devices in the treatment of saphenous vein bypass graft disease
  5. An assessment of renal function before the procedure (including glomerular filtration rate) and the documentation of contrast used during the procedure
  6. Documentation of the radiation dose used during the procedure
  7. The prescription of optimal medical therapy at discharge (aspirin, PY12 inhibitors and statins)   
  8. A referral to an outpatient cardiac rehabilitation program (to reduce the risk of recurrent events)   
  9. Participation in a regional or national PCI registry  
  10. The average annual volume of PCIs performed by the physician over the last two calendars years
  11. The average annual volume of PCIs performed by the hospital over the last calendar year
 
Measures 1, 3, 5, 7, 8, 9 and 11 are performance measures, while 2, 4, 6, and 10 are quality metrics. Quality metrics may not meet all specifications of formal performance measures or may be associated with unintended consequences of public reporting.
 
According to the writing committee, the measures may “serve as vehicles to accelerate appropriate translation of scientific evidence into clinical practice.” The committee goal was to create measures that capture many important aspects of quality while minimizing the reporting burden.
 
“Hospitals and health systems are increasingly facing a burden with measurement across multiple conditions and services,” said Carl Tommaso, M.D., interventional cardiologist, NorthShore University HealthSystem, and writing committee co-chair. “We wanted to focus on those aspects of PCI care that we thought would give us the greatest yield in terms of improving patient care.”
 
Brahmajee Nallamothu, M.D., associate professor of cardiovascular medicine, Department of Internal Medicine, University of Michigan, and writing committee co-chair, said this document is the first step in the evolving process of performance measurement.  
 
“Through these measures, we have moved beyond simple measurement of a few treatments to incorporating key concepts like appropriateness,” said Nallamothu. “There is still much more work to be done, however, and an important part of this process was to identify important areas for future investigation.”
 
The committee identified four areas of research that will generate better performance measures in the future:
  1. Measuring the filling of prescriptions (not just the prescription of drugs) and optimal dosing
  2. Better utilizing current data systems to track PCI quality
  3. Building accountability by all practitioners involved into quality metrics
  4. Utilizing patient surveys to track performance
 
The 2013 Performance Measures for Adults Undergoing Percutaneous Coronary Intervention is available on the ACC website and AHA websites and in future print issues of Journal of the American College of Cardiology (JACC) and Circulation: Journal of the American Heart Association.
 
For more information: www.cardiosource.org, www.americanheart.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Healthcare cybersecurity concerns have increased dramatically as EMRs and medical devices become more digitally connected.

Healthcare cybersecurity concerns have increased dramatically as EMRs and medical devices become more digitally connected.

Feature | Cybersecurity| August 18, 2017 | Dave Fornell
August 17, 2017 — Cybersecurity has become a growing concern in healthcare as patient data, medical systems and impla
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Overlay Init